JAK inhibitors are a class of drugs that calm an overactive immune system by blocking specific enzymes called Janus kinases (JAKs) inside your cells. These enzymes act as relay switches for inflammatory signals, so when they’re blocked, the cascade of inflammation slows down. JAK inhibitors are used to treat autoimmune and inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis, as well as certain blood cancers.
How They Work Inside Your Cells
Your immune system communicates through chemical messengers called cytokines. When a cytokine docks onto the outside of a cell, it triggers a chain reaction inside. First, the JAK enzymes attached to the receptor activate each other. Then they modify the receptor so it can recruit signaling proteins called STATs. Those STAT proteins pair up and travel into the cell’s nucleus, where they switch on genes that drive inflammation, cell growth, or immune responses.
JAK inhibitors are small molecules that slip inside the cell and compete with ATP, the energy molecule that JAK enzymes need to function. By occupying the spot where ATP would normally bind, the drug prevents the enzyme from firing. The entire downstream signal stalls, and the genes responsible for inflammation stay quiet. This is fundamentally different from biologic drugs like TNF inhibitors, which work outside the cell by neutralizing individual cytokines. JAK inhibitors block the internal wiring that multiple cytokines share, giving them a broader reach.
Conditions They Treat
The FDA has approved several JAK inhibitors for inflammatory and autoimmune diseases. Tofacitinib (Xeljanz) is approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and a form of childhood arthritis. Baricitinib (Olumiant) and upadacitinib (Rinvoq) are also approved for rheumatoid arthritis, with upadacitinib carrying additional approvals for atopic dermatitis and other inflammatory conditions. Abrocitinib (Cibinqo) targets atopic dermatitis specifically.
A separate group of JAK inhibitors treats blood disorders rather than inflammatory disease. Ruxolitinib (Jakafi) and fedratinib (Inrebic) are used for myelofibrosis, a condition where scar tissue builds up in bone marrow. A topical form of ruxolitinib (Opzelura) is applied as a cream for skin conditions like atopic dermatitis and vitiligo. Deucravacitinib (Sotyktu), which selectively targets TYK2 (a member of the JAK family), is approved for plaque psoriasis.
Oral vs. Topical Forms
Most JAK inhibitors come as daily oral tablets, but topical creams are available for skin conditions. For atopic dermatitis, studies have found that topical JAK inhibitors applied directly to affected skin were actually more effective than oral versions at reducing eczema severity scores. In animal models, topical application reduced both itching and inflammation, while oral versions primarily eased itching alone. The topical route also limits how much drug enters the bloodstream, which may reduce the systemic side effects that come with oral use.
How Quickly They Work
One of the appealing features of JAK inhibitors is their relatively fast onset. Many patients notice improvement within the first one to two months of treatment. In studies of inflammatory muscle and skin disease, about 41% of patients showed measurable improvement by one to two months, and an additional 39% improved by three months. Some patients experience meaningful relief as early as four weeks, though a complete response can take up to six months. This timeline is generally faster than older immune-suppressing drugs, which often require three to six months before taking full effect.
Selective vs. Broad JAK Inhibition
There are four JAK enzymes in the body: JAK1, JAK2, JAK3, and TYK2. Each pairs with different cytokine receptors, so blocking one has different effects than blocking another. Some drugs are designed to preferentially target just one, like JAK1-selective inhibitors (upadacitinib, abrocitinib) or TYK2-selective inhibitors (deucravacitinib). Others, like tofacitinib, inhibit multiple JAKs more broadly.
The theory behind selectivity is that targeting one JAK should reduce side effects linked to blocking the others. In real-world data, JAK1-selective inhibitors showed a trend toward fewer treatment discontinuations due to side effects (about 17%) compared to broad-spectrum JAK inhibitors (about 25%), though this difference wasn’t statistically significant. Serious adverse events occurred at similar rates in both groups, around 4 to 5%. Selectivity does have limits: as drug levels rise in the body, even a “selective” inhibitor starts affecting other JAK family members.
How They Compare to TNF Inhibitors
TNF inhibitors (like adalimumab and etanercept) have been the standard biologic treatment for rheumatoid arthritis for over two decades. A meta-analysis comparing JAK inhibitors head-to-head with TNF inhibitors found that JAK inhibitors produced a statistically significant improvement in physical function scores. They also showed superior disease activity reduction overall. However, the two classes performed similarly on some measures, including composite disease activity scores and patient-reported global assessments. For many patients, JAK inhibitors are positioned as a second-line option after TNF inhibitors, partly because of the safety concerns described below.
Safety Risks and FDA Warnings
JAK inhibitors carry a boxed warning, the FDA’s most serious safety label. This followed a large clinical trial of tofacitinib that revealed increased risks of serious cardiovascular events (heart attack, stroke), blood clots, cancer, and death compared to TNF inhibitors. The hazard ratio for cardiovascular events was 1.33, meaning the risk was about a third higher with tofacitinib. For cancers (excluding common skin cancers), the hazard ratio was 1.48. Lymphoma and lung cancer occurred more frequently, and the lung cancer risk was particularly elevated in current or former smokers.
Because baricitinib and upadacitinib share the same mechanism as tofacitinib, the FDA extended the boxed warning to those drugs as well, even though they haven’t been studied in a comparable large safety trial. Blood clots, including pulmonary embolism and deep vein thrombosis, were another notable risk, with evidence of a dose-dependent relationship: higher doses carried greater risk.
Blood Tests and Monitoring
Before starting a JAK inhibitor, your doctor will order a set of baseline blood tests. These typically include a complete blood count (checking your white blood cells, red blood cells, and platelets), a cholesterol panel, liver enzyme levels, and a kidney function test. Kidney function matters because it determines your starting dose; reduced kidney function usually means a lower dose.
You’ll repeat most of these tests between 8 and 12 weeks after starting treatment. This window catches the majority of patients who are susceptible to drug-related changes in blood counts or cholesterol. JAK inhibitors commonly raise LDL cholesterol, so your lipid levels will be tracked. If your results at that 8-to-12-week check are stable and unremarkable, ongoing routine lab monitoring is generally unnecessary for conditions like atopic dermatitis, though your doctor may continue periodic checks based on your individual risk factors. For rheumatoid arthritis and other systemic inflammatory conditions, monitoring intervals may be more frequent given the higher-risk patient population.